A Phase 3 interventional study of Sildenafil citrate and Sildenafil citrate in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 39 sites in 15 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 7 in phase 3, and was the 1st registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:
Silvia Ulrich · Sites in Switzerland
Ages 18–80
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 8 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 23 across the 18 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
14 studies in Pulmonary Arterial Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 9 finished, 8 (89%) have results posted.
Among the 14 studies in Pulmonary Arterial Hypertension by Viatris Inc., this one is the only one that started in 2004, is one of 3 in phase 3, and was the 1st registered.
Viatris Inc.’s Pulmonary Arterial Hypertension studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 14 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
Drug: Sildenafil citrate
Drug: Sildenafil citrate
As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
Drug: Sildenafil citrate
Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight \>20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight \>45 kg: 80 mg 3 times a day (tid)
Oral,10 mg 3 times a day (tid), only subjects with body weight \>20 kg
Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight \>20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight \>45 kg: 40 mg 3 times a day (tid)
Number of Participants Reporting at Least One Adverse Event
Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.
Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Number of Participants Reporting Treatment-related Adverse Events
Safety was measured according to standard adverse event collection as described in the adverse event section of the results.
Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Number of Participants Reporting at Least One Serious Adverse Event
Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the serious adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.
Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Number of Participants Reporting Treatment-related Serious Adverse Events
All serious adverse events regardless of treatment group or suspected relationship to study drug were reported. Investigators were to provide independent determination of possible causality of any serious adverse event.
Time frame: Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation)
Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration
Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.
Time frame: Pre-DMC Recommendation dose down titration (04 August 2011)
Number of Deaths Reported During This Study
Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.
Time frame: Last follow-up visit or 30 days after the last administration of study drug
Discontinuation Due to Intolerability
Participant who experienced drug-related intolerance, the participant's dose was reduced by 50%. If, after a dose reduction, the participant continued to appear intolerant, they were discontinued from study treatment.
Time frame: Throughout the treatment duration (median treatment duration 1689 to 1744 days)
Downtitration in Dose Due to Intolerability.
Based on review of the survival data, DMC concluded that the high dose of sildenafil was associated with a harmful effect on survival when compared to the low dose. The DMC also expressed concern as to the potential dose-response relationship between increasing dose and mortality. Therefore, on 04 August 2011, the DMC recommended discontinuation of the 40 mg and 80 mg three times a day (TID) doses, as well as the 20 mg TID dose in children with body weight ≤20 kg. The protocol was amended per DMC recommendations.
Time frame: Pre-DMC recomendation (04 August 2011)
Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests
Visual Acuity is measured either using the reduced Snellen test or via Teller cards, and was assessed in the left and right eyes separately. There were 9 lines on the reduced Snellen chart which were coded as 6/60, 6/36, 6/24, 6/18, 6/12, 6/9, 6/6, 6/5, 6/4 (where 6/60 was the easiest to read and 6/4 was the most difficult to read). If a participant experienced a visual adverse event the investigator was asked to perform additional ocular assessments either at the visit when the participant reported the visual adverse event or at an unplanned visit.
Time frame: Week 36
Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests.
Colour vision was measured where appropriate via the Farnsworth-Munsell D-15 Hue test. This test was performed in both eyes simultaneously or just in a single specific eye. If using a single eye the same eye was used throughout the study. In case of young participants an age-and-ability-appropriate evaluation such as the Ishihara Test for Unlettered Persons were conducted.
Time frame: Week 36
Pediatric Cognitive Development Status at Week 16.
Participant's cognitive development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
Time frame: Week 16
Pediatric Cognitive Development Status at Week 52.
Participant's cognitive development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
Time frame: Week 52
Pediatric Motor Development Status at Week 16.
Participant's motor development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
Time frame: Week 16
Pediatric Motor Development Status at Week 52
Participant's motor development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
Time frame: Week 52
Peak Volume of Oxygen (VO2) Consumed at Year 1 Using a Bicycle Ergometry Cardiopulmonary Exercise Test (CPX)
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the peak volume of VO2 consumed. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant
Time frame: 1 year
Percentage Change From Baseline in Percent Predicted Peak VO2 at Year 1.
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the percent predicted peak VO2 at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
Time frame: Baseline, Year 1
Percent Change From Baseline in Time to Maximum VO2 at Year 1
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the time to maximum VO2. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
Time frame: Baseline, Year 1
Percent Change From Baseline in Respiratory Exchange Ratio at Year 1
This is the ratio of carbon dioxide (CO2) produced to O2 consumed \[VCO2/VO2\]. Exercise Tolerance Test was performed on developmentally able participants to determine the respiratory exchange ratio on week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913).
Time frame: Baseline, Year 1
Percent Change From Start of Sildenafil in Total Ventilation (VE) to Year 1
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the total ventilation. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
Time frame: Year 1
Percentage Change From Baseline in End Tidal Oxygen (O2) at Year 1.
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal O2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
Time frame: Baseline, Year 1
Percentage Change From Baseline in End Tidal Carbon Dioxide (CO2) at Year 1.
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal CO2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
Time frame: Baseline, Year 1
Percentage Change From Baseline in Anaerobic Threshold at Year 1.
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the anaerobic threshold at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
Time frame: Baseline, Year 1
Summary of Shift in Changes From Start of Sildenafil in World Health Organization Pulmonary Hypertension (WHO PH) Functional Class by A1481156 Treatment Group at Year 1.
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarized at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.
Time frame: Baseline, Year 1
Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 2.
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.
Time frame: Baseline, Year 2
Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 3.
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 (NCT00159913) baseline at Years 1, 2, 3 and 4 were evaluated.
Time frame: Baseline, Year 3
Summary of Shift in Changes From Start of Sildenafil in WHO PH Functional Class by A1481156 Treatment Group at Year 4.
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.
Time frame: Baseline, Year 4
Additions From Baseline in Background Therapy up to the End of Study
This was defined as an addition or discontinuation in the class(es) of drugs used as background medication (e.g., anticoagulants, oxygen, diuretics, calcium channel blockers, and digoxin) compared to baseline of Study A1481131 (NCT00159913).
Time frame: Up to the end of study
Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Psychosocial Scale at Year 1.
CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
Time frame: Baseline, Year 1
Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Physical Scale at Year 1.
CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
Time frame: Baseline, Year 1
Participant (Parent) Global Assessment at Year 1
The participant (parent) global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.
Time frame: Year 1
Physician Global Assessment at Year 1
The physician global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants with markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.
Time frame: Year 1
This extension study included 220 participants at 31 sites. 14 participants did not go from A1481131 (NCT00159913) to A1481156. Participants from one center in Canada participated in base study A1481131 (NCT00159913) but not in this extension study.
| Milestone | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Started | 42 | 55 | 77 | 13 | 19 | 23 | 5 |
| Treated | 42 | 55 | 77 | 13 | 19 | 23 | 5 |
| Completed | 22 | 25 | 34 | 7 | 11 | 11 | 0 |
| Not completed | 20 | 30 | 43 | 6 | 8 | 12 | 5 |
| Withdrew: Adverse event | 2 | 2 | 5 | 1 | 1 | 2 | 0 |
| Withdrew: Does not meet entrance criteria | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 1 | 1 | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 | 0 | 1 | 2 | 1 |
| Withdrew: Other | 8 | 8 | 8 | 0 | 2 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 5 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 3 | 8 | 15 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 6 | 8 | 4 | 3 | 2 | 1 |
| Withdrew: Pregnancy | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Number of Participants Reporting at Least One Adverse Event | 41 | 55 | 73 | 13 | 19 | 22 | 3 |
Safety was measured according to standard adverse event collection as described in the adverse event section of the results.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Treatment-related Adverse Events | 20 | 24 | 41 | 9 | 9 | 11 | 3 |
Safety was measured according to standard adverse event collection as described in the adverse event section of the results. Complete tables of the serious adverse events according to the A1481156 treatment groups are provided in the reported adverse event section.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Number of Participants Reporting at Least One Serious Adverse Event | 13 | 33 | 38 | 1 | 4 | 10 | 0 |
All serious adverse events regardless of treatment group or suspected relationship to study drug were reported. Investigators were to provide independent determination of possible causality of any serious adverse event.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Treatment-related Serious Adverse Events | 1 | 1 | 4 | 0 | 0 | 0 | 0 |
Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Number of Deaths Reported in the Study Prior to the Data Monitoring Committee (DMC) Recommendation of Dose Down Titration | 5 | 10 | 22 |
Deaths were reported immediately independent of the circumstances or suspected cause at any time during the study through the last follow-up visit or 30 days after the last administration of study drug, whichever comes later.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Number of Deaths Reported During This Study | 5 | 13 | 24 |
Participant who experienced drug-related intolerance, the participant's dose was reduced by 50%. If, after a dose reduction, the participant continued to appear intolerant, they were discontinued from study treatment.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Discontinuation Due to Intolerability | 2 | 1 | 3 |
Based on review of the survival data, DMC concluded that the high dose of sildenafil was associated with a harmful effect on survival when compared to the low dose. The DMC also expressed concern as to the potential dose-response relationship between increasing dose and mortality. Therefore, on 04 August 2011, the DMC recommended discontinuation of the 40 mg and 80 mg three times a day (TID) doses, as well as the 20 mg TID dose in children with body weight ≤20 kg. The protocol was amended per DMC recommendations.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Downtitration in Dose Due to Intolerability. | 0 | 0 | 3 | 0 | 2 | 1 | 0 |
Visual Acuity is measured either using the reduced Snellen test or via Teller cards, and was assessed in the left and right eyes separately. There were 9 lines on the reduced Snellen chart which were coded as 6/60, 6/36, 6/24, 6/18, 6/12, 6/9, 6/6, 6/5, 6/4 (where 6/60 was the easiest to read and 6/4 was the most difficult to read). If a participant experienced a visual adverse event the investigator was asked to perform additional ocular assessments either at the visit when the participant reported the visual adverse event or at an unplanned visit.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Number of Participants With Deterioration Post Baseline in Visual Acuity Safety Tests | 10 | 11 | 17 | 0 | 4 | 4 | 0 |
Colour vision was measured where appropriate via the Farnsworth-Munsell D-15 Hue test. This test was performed in both eyes simultaneously or just in a single specific eye. If using a single eye the same eye was used throughout the study. In case of young participants an age-and-ability-appropriate evaluation such as the Ishihara Test for Unlettered Persons were conducted.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Number of Participants With Deterioration Post Baseline in Color Vision Monitoring Safety Tests. | 2 | 2 | 1 | 0 | 0 | 1 | 1 |
Participant's cognitive development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Severely Limited | 2 | 4 | 2 | 0 | 1 | 1 | 0 |
| Moderately Limited | 5 | 6 | 8 | 1 | 5 | 2 | 1 |
| Mildly Limited | 6 | 7 | 12 | 1 | 1 | 1 | 0 |
| Not Limited | 26 | 38 | 54 | 11 | 12 | 19 | 1 |
Participant's cognitive development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's cognitive development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose |
|---|---|---|---|---|---|---|
| Severely Limited | 1 | 1 | 2 | 0 | 0 | 0 |
| Moderately Limited | 5 | 10 | 6 | 1 | 5 | 2 |
| Mildly Limited | 3 | 5 | 8 | 0 | 3 | 3 |
| Not Limited | 27 | 36 | 50 | 11 | 10 | 15 |
Participant's motor development status was assessed at A1481156 baseline (Week 16 in A1481131; NCT00159913) using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Severely Limited | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Moderately Limited | 5 | 5 | 7 | 0 | 4 | 1 | 1 |
| Mildly Limited | 10 | 11 | 20 | 1 | 5 | 2 | 0 |
| Not Limited | 24 | 39 | 49 | 12 | 9 | 20 | 1 |
Participant's motor development status was assessed at Week 52 using the physician assessment questions. Assessment question (i.e., compared to other children the participant's age group is this participant's motor development limited?) included the following criteria : severely limited, moderately limited, mildly limited and not limited.
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose |
|---|---|---|---|---|---|---|
| Severely Limited | 0 | 0 | 0 | 0 | 0 | 0 |
| Moderately Limited | 4 | 9 | 5 | 0 | 2 | 0 |
| Mildly Limited | 8 | 8 | 15 | 3 | 6 | 3 |
| Not Limited | 24 | 35 | 46 | 9 | 10 | 17 |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the peak volume of VO2 consumed. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant
| mL/kg/min | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Peak Volume of Oxygen (VO2) Consumed at Year 1 Using a Bicycle Ergometry Cardiopulmonary Exercise Test (CPX) | 19.97 ± 5.17 | 18.69 ± 5.92 | 17.93 ± 4.02 |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the percent predicted peak VO2 at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
| Percent | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Percentage Change From Baseline in Percent Predicted Peak VO2 at Year 1. | 12.79 ± 22.71 | 7.65 ± 34.57 | 5.83 ± 23.54 | 8.70 ± 25.99 | 0.20 ± 22.32 | -6.13 ± 7.46 | NA ± NA |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the time to maximum VO2. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
| Percent | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Time to Maximum VO2 at Year 1 | 25.47 ± 35.67 | 13.08 ± 33.42 | 7.70 ± 33.01 | 21.17 ± 57.25 | 36.68 ± 101.65 | -9.64 ± 15.21 | NA ± NA |
This is the ratio of carbon dioxide (CO2) produced to O2 consumed \[VCO2/VO2\]. Exercise Tolerance Test was performed on developmentally able participants to determine the respiratory exchange ratio on week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913).
| Percent | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Respiratory Exchange Ratio at Year 1 | 2.15 ± 8.73 | 5.63 ± 13.37 | 0.68 ± 11.50 | -3.69 ± 7.24 | 0.27 ± 11.04 | 10.75 ± 17.76 | NA ± NA |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to determine the total ventilation. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
| Percent | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Percent Change From Start of Sildenafil in Total Ventilation (VE) to Year 1 | 14.29 ± 21.38 | 12.38 ± 32.64 | 11.80 ± 19.79 |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal O2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
| Percent | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Percentage Change From Baseline in End Tidal Oxygen (O2) at Year 1. | 0.59 ± 3.79 | -0.52 ± 3.55 | 0.08 ± 3.68 |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the End Tidal CO2 at Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
| Percent | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Percentage Change From Baseline in End Tidal Carbon Dioxide (CO2) at Year 1. | 7.83 ± 16.35 | 7.68 ± 18.74 | 13.16 ± 31.38 |
Exercise Tolerance Test (CPX test) was performed on developmentally able participants to measure the anaerobic threshold at Week 16 and Year 1. Participants were assumed to be developmentally able if they had a CPX exercise assessment at any visit during study A1481131 (NCT00159913). The CPX tests were performed as close to trough plasma levels of sildenafil as possible, i.e., prior to dosing and at least 4 hours after the previous dose. If participants were able to perform the CPX test in Study A1481131 (NCT00159913), they were expected to be able to perform the exercise paradigm in the extension study (A1481156) unless their clinical condition had deteriorated and the investigator considered this was unsafe for the participant.
| Percent | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Percentage Change From Baseline in Anaerobic Threshold at Year 1. | -1.22 ± 23.06 | 1.99 ± 29.54 | 3.28 ± 29.36 | 7.23 ± 12.31 | -3.59 ± 28.29 | 8.96 ± 32.55 | NA ± NA |
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarized at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Improved by 3 Classes | 0 | 0 | 0 |
| Improved by 2 Classes | 1 | 0 | 1 |
| Improved by 1 Class | 13 | 15 | 19 |
| No change | 30 | 48 | 64 |
| Worsened by 1 Class | 4 | 6 | 3 |
| Worsened by 2 Classes | 1 | 0 | 0 |
| Worsened by 3 Classes | 0 | 0 | 0 |
| Discontinued | 5 | 4 | 10 |
| Died | 0 | 0 | 1 |
| Missing | 1 | 1 | 2 |
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Improved by 3 Classes | 0 | 0 | 0 |
| Improved by 2 Classes | 0 | 1 | 1 |
| Improved by 1 Class | 11 | 11 | 16 |
| No change | 28 | 47 | 55 |
| Worsened by 1 Class | 3 | 2 | 5 |
| Worsened by 2 Classes | 0 | 0 | 0 |
| Worsened by 3 Classes | 0 | 0 | 0 |
| Discontinued | 9 | 9 | 16 |
| Died | 1 | 2 | 5 |
| Missing | 3 | 2 | 2 |
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 (NCT00159913) baseline at Years 1, 2, 3 and 4 were evaluated.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Improved by 3 Classes | 0 | 0 | 0 |
| Improved by 2 Classes | 1 | 0 | 1 |
| Improved by 1 Class | 11 | 16 | 17 |
| No change | 21 | 36 | 44 |
| Worsened by 1 Class | 3 | 3 | 5 |
| Worsened by 2 Classes | 1 | 0 | 1 |
| Worsened by 3 Classes | 0 | 0 | 0 |
| Discontinued | 14 | 13 | 19 |
| Died | 2 | 3 | 9 |
| Missing | 2 | 3 | 4 |
The WHO PH functional classification was as follows: Class I : Participants with PH but without resulting limitation of physical activity. Class II : Participants with PH resulting in slight limitation of physical activity. Class III : Participants with PH resulting in marked limitation of physical activity. Class IV : Participants with PH with inability to carry out any physical activity without symptoms. Changes from baseline in functional class were summarised at Years 1, 2, 3, and 4. Numbers of participants improving by 3 classes, improving by 2 classes, improving by 1 class, not changing, worsening by 1 class, worsening by 2 classes or worsening by 3 classes from A1481131 baseline at Years 1, 2, 3 and 4 were evaluated.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Improved by 3 Classes | 0 | 0 | 0 |
| Improved by 2 Classes | 0 | 0 | 2 |
| Improved by 1 Class | 13 | 14 | 16 |
| No change | 15 | 29 | 41 |
| Worsened by 1 Class | 6 | 4 | 5 |
| Worsened by 2 Classes | 1 | 2 | 1 |
| Worsened by 3 Classes | 0 | 0 | 0 |
| Discontinued | 15 | 18 | 20 |
| Died | 2 | 5 | 13 |
| Missing | 3 | 2 | 2 |
This was defined as an addition or discontinuation in the class(es) of drugs used as background medication (e.g., anticoagulants, oxygen, diuretics, calcium channel blockers, and digoxin) compared to baseline of Study A1481131 (NCT00159913).
| Participants | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| All Classes (N = 18, 26, 43, 7, 8, 14, 4) | 6 | 5 | 11 | 2 | 1 | 2 | 1 |
| At least one class (N = 42, 55, 77, 13, 19, 23, 5) | 13 | 13 | 23 | 3 | 5 | 2 | 1 |
CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
| Units on a scale | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Psychosocial Scale at Year 1. | 5.63 ± 7.70 | 3.92 ± 10.25 | 3.48 ± 12.55 | 13.74 ± 12.42 | 5.30 ± 9.30 | 4.27 ± 12.19 | NA ± NA |
CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.
| Units on a scale | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF28) as Assessed by the Physical Scale at Year 1. | 14.29 ± 11.06 | 9.34 ± 13.45 | 5.91 ± 10.17 | 8.51 ± 13.27 | 9.86 ± 17.93 | 4.64 ± 12.03 | NA ± NA |
The participant (parent) global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Markedly Improved | 9 | 14 | 21 |
| Moderately Improved | 13 | 27 | 26 |
| Mild Improvement | 12 | 15 | 15 |
| No Change | 13 | 6 | 21 |
| Slightly Worse | 1 | 2 | 0 |
| Moderately Worse | 0 | 1 | 0 |
| Markedly Worse | 0 | 0 | 0 |
| Discontinued | 5 | 4 | 10 |
| Died | 0 | 0 | 1 |
| Missing | 2 | 5 | 6 |
The physician global assessment of disease severity was assessed at Year 1 in this extension study. The number and percentage of participants with markedly improved, moderately improved, mild improvement, no change, slightly worse, moderately worse, markedly worse were evaluated. Participants who withdrew from study treatment after at least 10 weeks of treatment were requested to perform the global assessments.
| Participants | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Markedly Improved | 6 | 6 | 6 |
| Moderately Improved | 8 | 18 | 27 |
| Mild Improvement | 19 | 26 | 37 |
| No Change | 15 | 16 | 17 |
| Slightly Worse | 1 | 1 | 0 |
| Moderately Worse | 0 | 1 | 0 |
| Markedly Worse | 0 | 0 | 0 |
| Discontinued | 5 | 4 | 10 |
| Died | 0 | 0 | 1 |
| Missing | 1 | 2 | 2 |
Collected over Up to Follow-Up visit (30 to 40 days after study completion or treatment discontinuation). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sildenafil Low Dose | — | 14/55 (25.5%) | 51/55 (92.7%) |
| Sildenafil Medium Dose | — | 37/74 (50%) | 70/74 (94.6%) |
| Sildenafil High Dose | — | 48/100 (48%) | 87/100 (87%) |
| Event | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/55 | 7/74 | 10/100 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 0/55 | 2/74 | 7/100 |
| Cardiac failureCardiac disorders | 2/55 | 2/74 | 6/100 |
| Upper respiratory tract infectionInfections and infestations | 0/55 | 1/74 | 6/100 |
| Chest painGeneral disorders | 3/55 | 0/74 | 2/100 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 2/55 | 4/74 | 5/100 |
| Right ventricular failureCardiac disorders | 2/55 | 3/74 | 3/100 |
| GastroenteritisInfections and infestations | 0/55 | 3/74 | 3/100 |
| SyncopeNervous system disorders | 2/55 | 2/74 | 1/100 |
| Dental cariesGastrointestinal disorders | 0/55 | 1/74 | 3/100 |
| Event | Sildenafil Low Dose | Sildenafil Medium Dose | Sildenafil High Dose |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/55 | 22/74 | 37/100 |
| HeadacheNervous system disorders | 18/55 | 18/74 | 26/100 |
| PharyngitisInfections and infestations | 16/55 | 13/74 | 13/100 |
| NasopharyngitisInfections and infestations | 15/55 | 11/74 | 17/100 |
| VomitingGastrointestinal disorders | 14/55 | 13/74 | 24/100 |
| PyrexiaGeneral disorders | 7/55 | 16/74 | 16/100 |
| BronchitisInfections and infestations | 10/55 | 16/74 | 16/100 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/55 | 14/74 | 17/100 |
| DiarrhoeaGastrointestinal disorders | 10/55 | 11/74 | 16/100 |
| InfluenzaInfections and infestations | 10/55 | 6/74 | 12/100 |
| Age, Customized(Participants) | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized | Total |
|---|---|---|---|---|---|---|---|---|
| 1-4 | 0 | 9 | 19 | 1 | 3 | 2 | 1 | 35 |
| 5-12 | 25 | 28 | 36 | 11 | 10 | 14 | 2 | 126 |
| 13-17 | 17 | 18 | 22 | 1 | 6 | 7 | 2 | 73 |
| >=18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sildenafil Low/Low Dose | Sildenafil Medium/ Medium Dose | Sildenafil High/ High Dose | Placebo/ Low Dose | Placebo/ Medium Dose | Placebo/ High Dose | Placebo Non-randomized | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 25 | 31 | 51 | 9 | 11 | 15 | 3 | 145 |
| Male | 17 | 24 | 26 | 4 | 8 | 8 | 2 | 89 |
The record gives a start of Jan 2004, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pulmonary Arterial Hypertension →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →